Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

Delayed Quote. Delayed  - 04/28 09:59:45 pm
1.77 USD   +0.57%
04/22 PLURISTEM THERA : Enters Into Licensing Agreement with TES Holdings ..
04/21 Pluristem Enters into Licensing Agreement with TES Holdings Co., ..
04/14 PLURISTEM THERA : Continues to Strengthen its Position in Japan Gran..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/22/2016 04/25/2016 04/26/2016 04/27/2016 04/28/2016 Date
1.77(c) 1.85(c) 1.81(c) 1.76(c) 1.77(c) Last
77 053 169 520 92 050 119 532 40 226 Volume
+1.14% +4.52% -2.16% -2.76% +0.57% Change
More quotes
Financials ($)
Sales 2016 2,97 M
EBIT 2016 -24,8 M
Net income 2016 -25,0 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,93 M
EBIT 2017 -30,4 M
Net income 2017 -27,8 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 47,7x
Capi. / Sales 2017 152x
Capitalization 142 M
More Financials
Company
Pluristem Therapeutics, Inc. engages in the development of standardized cell therapy products for the treatment of life threatening diseases.Its patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
04/22 PLURISTEM THERAPEUTICS : Enters Into Licensing Agreement with TES Holdings Co., ..
04/21 Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a vent..
04/14 PLURISTEM THERAPEUTICS : Continues to Strengthen its Position in Japan Granted T..
04/13 Pluristem Continues to Strengthen its Position in Japan – Granted Two K..
03/02 PLURISTEM THERAPEUTICS INC. : Pluristem's Radiation Antidote Bests Blockbuster D..
02/17 PLURISTEM THERAPEUTICS : National Institutes of Healths NIAID Initiating Dose Ev..
02/16 National Institutes of Health’s NIAID Initiating Dose Evaluation Studie..
02/10 Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinica..
More news
Sector news : Biotechnology & Medical Research - NEC
07:12a SANOFI : leading fresh round of pharma M&A
04/28 SEATTLE GENETICS : reports 1Q loss
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
04/13 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
02/22 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
02/17 Pluristem adds to up move stoked by improved prospects for PLX-R18; shares up..
02/17 Midday Gainers/ Losers
02/17 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am


Comments 
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Technical analysis trends PLURISTEM THERAPE...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions